Roche continues strong momentum with 7% growth (CER) in the first half of 2025 – full-year outlook confirmed. For more details on our performance, click here ➡️ https://xmrrwallet.com/cmx.pgo.roche.com/hfrli #RocheFinancialResults
Info
Roche ist ein globales Unternehmen mit Vorreiterrolle in der Erforschung und Entwicklung von Medikamenten und Diagnostika und ist darauf fokussiert, Menschen durch wissenschaftlichen Fortschritt ein besseres, längeres Leben zu ermöglichen. Dank der Kombination von Pharma und Diagnostika unter einem Dach ist Roche führend in der personalisierten Medizin - einer Strategie mit dem Ziel, jeder Patientin und jedem Patienten die bestmögliche Behandlung zukommen zu lassen. Roche ist das grösste Biotech-Unternehmen weltweit mit differenzierten Medikamenten für die Onkologie, Immunologie, Infektionskrankheiten, Augenheilkunde und Erkrankungen des Zentralnervensystems. Roche ist auch der bedeutendste Anbieter von In-vitro-Diagnostika und gewebebasierten Krebstests und ein Pionier im Diabetesmanagement. Seit der Gründung im Jahr 1896 erforscht Roche bessere Wege, um Krankheiten zu verhindern, zu erkennen und zu behandeln und leistet einen nachhaltigen Beitrag zur gesellschaftlichen Entwicklung. Zum Ziel des Unternehmens gehört es durch Kooperationen mit allen relevanten Partnern den Zugang von Patienten zu medizinischen Innovationen zu verbessern. Auf der Liste der unentbehrlichen Arzneimittel der Weltgesundheitsorganisation stehen heute 30 von Roche entwickelte Medikamente, darunter lebensrettende Antibiotika, Malariamittel und Krebsmedikamente. Ausgezeichnet wurde Roche zudem bereits das neunte Jahr in Folge als das nachhaltigste Unternehmen innerhalb der Pharma-, Biotechnologie- und Life-Sciences-Branche im Dow Jones Sustainability Index. Die Roche-Gruppe mit Hauptsitz in Basel, Schweiz ist in über 100 Ländern tätig und beschäftigte 2017 weltweit rund 94 000 Mitarbeiterinnen und Mitarbeiter. Im Jahr 2017 investierte Roche CHF 10,4 Milliarden in Forschung und Entwicklung und erzielte einen Umsatz von CHF 53,3 Milliarden. Genentech in den USA gehört vollständig zur Roche-Gruppe. Roche ist Mehrheitsaktionär von Chugai Pharmaceutical, Japan. Weitere Informationen finden Sie unter www.roche.com/careers #Roche #Biotechnology #Pharmaceuticals #Diagnostics #Healthcare #PersonalizedHealthcare #GreatPlaceToWork #Innovation
- Website
-
http://xmrrwallet.com/cmx.pwww.roche.com/
Externer Link zu Roche
- Branche
- Biotechnologieforschung
- Größe
- 10.001+ Beschäftigte
- Hauptsitz
- Switzerland 🇨🇭
- Art
- Kapitalgesellschaft (AG, GmbH, UG etc.)
- Spezialgebiete
- biotechnology, innovation, personalized healthcare, great place to work, diagnostics, pharmaceuticals, research, healthcare, personalised healthcare, diabetes care, genomics, healthcare technology, big data und Science
Orte
Beschäftigte von Roche
Updates
-
What happens when young artists and scientists spend a week exploring the future together? We recently found out. From July 13–19, Roche Continents 2025 brought 40 exceptional minds to Arles, France, for a transformative week of dialogue, discovery and co-creation. This year's Futurescapes theme challenged participants to imagine what lies ahead—through the lens of sustainability, ethics, and the evolving human experience. In partnership with LUMA Arles, they moved between immersive workshops, intimate discussions, and unexpected collaborations, pushing the boundaries of how art and science can shape the world. The feedback was incredible: many called it "inspiring and life-changing," valuing the unique cross-disciplinary exchange and expressing a strong desire to stay connected and continue their collaboration. We leave inspired by their questions, their curiosity, and the connections forged across disciplines, cultures and perspectives. To everyone who took part: thank you for lighting the way forward. 👉 Learn more about the program: https://xmrrwallet.com/cmx.plnkd.in/gJ4eaJ8Q #RocheContinents2025 #Futurescapes #Art #Science #Innovation #RochePhilanthropy
-
-
Roche hat dies direkt geteilt
CEO Roche Group | Passionate about science, and committed to positively impacting people’s lives through healthcare
A strong first half for Roche with Group sales growing by 7% at constant exchange rates! I am pleased to share that our positive momentum continued and confirm our full-year outlook. Over the past six months, we have made significant progress in our pipeline and advanced four potentially practice-changing therapies into the final phase of clinical development. Looking forward, in the second half of 2025, we expect to see results from a number of phase III trials in breast cancer, severe eye diseases and multiple sclerosis. In Diagnostics, we continue to bring our breakthrough innovations to customers and patients, including the launch of our blood test for early Alzheimer’s detection. Thanks to all our teams around the world for their dedication and passion! #Strategy #Innovation #WeAreRoche
-
Roche hat dies direkt geteilt
CEO Roche Group | Passionate about science, and committed to positively impacting people’s lives through healthcare
A strong first half for Roche with Group sales growing by 7% at constant exchange rates! I am pleased to share that our positive momentum continued and confirm our full-year outlook. Over the past six months, we have made significant progress in our pipeline and advanced four potentially practice-changing therapies into the final phase of clinical development. Looking forward, in the second half of 2025, we expect to see results from a number of phase III trials in breast cancer, severe eye diseases and multiple sclerosis. In Diagnostics, we continue to bring our breakthrough innovations to customers and patients, including the launch of our blood test for early Alzheimer’s detection. Thanks to all our teams around the world for their dedication and passion! #Strategy #Innovation #WeAreRoche
-
As populations age and diabetes rates rise across Asia Pacific, the risk of preventable vision loss is increasing – placing pressure on individuals, families, and health systems. That's why APVRS and Roche joined forces to host the “Turning Insights into Action: Advancing Vision Health in Asia Pacific” webinar – a multi-stakeholder discussion focused on strengthening early detection, timely treatment, and integrated vision care across the region. Drawing on findings from the APAC Vision Health Survey, experts shared lived experiences and perspectives from diverse healthcare settings, highlighting the importance of collaborative approaches to protecting vision and improving outcomes. Watch the full discussion here: https://xmrrwallet.com/cmx.plnkd.in/ek3K2Ah3 #APVRS #APACVisionHealthSurvey #RocheOphthaAPAC #RocheOphthalmology Andrew Chang Mårten Brelén Nor Fariza Ngah Paisan Ruamviboonsuk Prof Seung Young Yu Ahmed Elhusseiny
-
Mass spectrometry has the potential to provide patients with more personalised diagnoses. But do you know what makes this technology a gold standard in clinical diagnostic testing? #massspectrometry #innovation #diagnostics #RocheMassSpec
Dieser Inhalt ist hier nicht verfügbar.
Mit der LinkedIn App können Sie auf diese und weitere Inhalte zugreifen.
-
Graduation season is a truly meaningful moment at Roche - seeing our talent grow and step into what’s next is inspiring. Together with our CEO Thomas Schinecker, we’re proud to celebrate 44 apprentices as they begin a new chapter. Join us in celebrating new beginnings, ongoing growth and staying curious. #WeAreRoche #GrowthMindset #EarlyCareers #Career
CEO Roche Group | Passionate about science, and committed to positively impacting people’s lives through healthcare
Just as the UEFA Women's EURO 2025 kicked off here in Switzerland, we were celebrating another kind of kickoff: a new chapter in many professional journeys. Last week, I joined 44 Roche apprentices to celebrate their graduation. Moments like these are among the most meaningful in any career – because they remind us where it all begins. I told our graduates: You don’t need to have it all mapped out. But one thing is clear – there are no shortcuts in life. If you want to achieve something, the only way to get there is through hard work and dedication. Football is a good reminder of many things: Teamwork matters. Preparation matters. Continuous learning and improvement matters. Last but not least, as a famous coach once said: “Nach dem Spiel ist vor dem Spiel.” In life – just like in football – you can’t rest on past successes. There’s always a next challenge. At Roche, we are investing in the next generation. Not just because it’s the right thing to do, but because we learn from them, too. They challenge how we do things. And they remind us to stay curious. More than half of this year’s apprentices will stay on at Roche – some as employees, others as students. That says a lot. About them, and about the people who guided them along the way. To all those finishing their training this summer – and to everyone who supported them: Congratulations – and thank you. Enjoy the moment!
-
-
What happens when young artists and scientists team up to build the future? 💡 We're about to find out! Next week, between July 13 and 19, Roche Continents 2025 brings together 40 of Europe’s brightest young minds to Arles, France, for a week of intense exploration and innovation. For over a decade, this program has united students from science and the arts to uncover where transformative ideas truly come from. This year's "Futurescapes" theme will challenge them to focus on sustainable development, ethical considerations, and the human experience within an evolving world. In partnership with LUMA Arles, participants will dive into hands-on workshops and interdisciplinary collaboration, creating solutions that drive positive change. Learn more about how we're empowering young minds to shape the future: https://xmrrwallet.com/cmx.plnkd.in/dEa4K9ZV #RocheContinents2025 #Futurescapes #Art #Science #Innovation
-
According to the UN World Population Prospects, the average life expectancy at birth in Europe is projected to increase from 79.5 years in 2025 to 84 years by 2050, with more people reaching the age of 100. But will those extra years be healthy? 🤔 New research commissioned by Roche and conducted by GWI reveals growing concerns about access to quality healthcare as populations age, making it a top public priority. The report also explores how innovation can play a key role in addressing these challenges. 📄 Discover more in our latest Insight Report below: 👇 #TheEraOfLongevity #HealthcareInnovation #FutureOfEurope #AgingPopulation
-
We're proud to renew our partnership with The Global Fund and extend our collaboration to enhance countries' diagnostics capacities to advance progress in waste management and the global fight against infectious disease. Over the last years, we have combined our expertise, resources, solution and networks to address systemic gaps preventing people living in low-and-middle income countries from accessing essential diagnostics services. Join us as we empower communities and health systems in achieving equitable access to care. Learn more about our journey: https://xmrrwallet.com/cmx.plnkd.in/dPUgAwH2 #AccessPartnerships #GlobalHealth
-
Verbundene Seiten
Ähnliche Seiten
Finanzierung
Roche
Insgesamt 4 Finanzierungsrunden
![]()
SoftBank
Weitere Informationen auf Crunchbase
Letzte Runde
Kapitalerhöhung nach Börsengang
Externer Crunchbase-Link für die letzte Finanzierungsrunde
5.000.000.000,00 $
Investor:innen